Black Diamond Therapeutics, Inc. BDTX

BACK THE TRUCK UP!

Stock is in a short term over bought condition. Time to cash out

506,000 Shares in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Purchased by Boxer Capital Management LLC
Written by MarketBeat
Updated May 6, 2025
Black Diamond Therapeutics logo with Medical background
Boxer Capital Management LLC acquired a new stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 506,000 shares of the company's stock, valued at approximately $1,083,000. Boxer Capital Management LLC owned 0.89% of Black Diamond Therapeutics at the end of the most recent reporting period.

Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating
MT Newswires
·
Mar 7 07:13
·
Ratings
1min
Black Diamond Therapeutics
(BDTX.US)
1.680
2.370
-1.75%
+41.07%

Black Diamond Therapeutics (BDTX) has an average rating of Buy and mean price target of $14.33, according to analysts polled by FactSet.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation

What are u guys

This is a massive buying opportunity. Learn people, learn. Sometimes stocks get massively overboard, and sometimes they get massively oversold. This is massively oversold!!! BUY BUY BUY